Lori Reilly (@lreilly71) profile picture

Mom, wife, Husker fan and passionate advocate for new cures and treatments for patients.

Joined October 2012
Nebraska volleyball sold more apparel through the NIL Store in September than any college football program in the country. 😳
5
62
6
554
10,361
Lori Reilly retweeted
"For hospitals eligible for 340(B) discounts, each Keytruda patient was associated with $102,680 in annual revenue..." Compared to: $67,825 at non-340B hospitals and $3,094 at physician practices.
3
27
8
71
20,280
Enjoyed joining yesterday’s #HillNationSummit with @KathleenKoch1 to discuss how America's biopharmaceutical industry strengthens our economy, our health security and our global competitiveness. Protecting the policies that fuel innovation will help ensure patients continue to benefit from the next generation of medicines. @TheHillEvents
1
2
1,358
🚨Good News: Former Nebraska Senator Ben Sasse has announced during an interview this week that his tumors have shrunk by 80% thanks in part to a new cancer drug Ben Sasse: “I'm down 99%, in five months, of how much cancer is in my blood.”
404
1,171
164
17,687
1,063,461
Important perspective from @steveubl on what’s at stake for America’s innovation leadership. The U.S. leads the world in biopharmaceutical innovation because we’ve built an ecosystem that supports investment, R&D and medical progress. Policies that weaken that foundation risk ceding ground to China at exactly the wrong time.
America’s leadership in biopharmaceutical innovation is not guaranteed. Harmful price-setting policies like MFN would weaken U.S. competitiveness just as China rapidly expands its investment in R&D and drug development. ow.ly/THBV50Zhk8z
128
Melissa’s story is a powerful reminder of what innovation makes possible. Breakthrough medicines saved her life, giving her more time with the people she loves. For Melissa—and for so many patients like her—we need the U.S. to continue leading in medical innovation. ow.ly/a1oi50ZcRcH
2
118
Navigating the health care system can be overwhelming for patients and families, especially as new ways to access care continue to emerge. America's Medicines was created to help people better understand their options to access their and their loved-ones’ prescribed medicines, find trusted information and feel more confident navigating their care journey. Explore here: ow.ly/BFjn50Zcprr
41
Biopharmaceutical innovation has made a real difference in people’s lives, bringing new hope to patients and families facing serious health challenges. Our latest ad highlights why America’s leadership and protecting access to new medicines is so important. Learn more at ow.ly/h0zq50Zc3PC
1
50
Every medical breakthrough represents new hope for patients and families. As this @Axios article highlights, advances in areas like gene therapy are creating new possibilities for people facing serious and complex diseases. While there is still much work ahead, continued innovation has the potential to transform how patients experience and manage disease, opening doors that once seemed out of reach. ow.ly/9og050Z9U9i
5
483
Our member company researchers from across the country are here in DC to share their stories directly with members of Congress. Thank you all not only for your time today, but your work every day in labs, developing the next life-changing treatments and cures.
4
122
Patients benefit when innovation and competition work together. Competition amongst innovators and then from generics and biosimilars can help lower costs over time while continued biopharmaceutical R&D helps drive new treatments and the next generation of medical progress.
Competition and innovation both play a critical role in America’s biopharmaceutical ecosystem. Competition among innovators and then from generics and biosimilars help lower costs over time while continued R&D drives new treatments and cures for patients. ow.ly/FkjU50Z6KJq
1
94
A photo I took in Normandy last year. Standing here made the scale of D-Day feel real in a way no book ever could. Today we remember the courage and sacrifice of the Allied forces who landed on these shores and changed history. #DDay
2
72
Lori Reilly retweeted
𝐓𝐡𝐞 𝐌𝐨𝐬𝐭 𝐈𝐦𝐩𝐨𝐫𝐭𝐚𝐧𝐭 340𝐁 𝐩𝐚𝐩𝐞𝐫 𝐘𝐨𝐮'𝐥𝐥 𝐄𝐯𝐞𝐫 𝐑𝐞𝐚𝐝 If you care about #340B policy, use the long weekend to read this outstanding new paper: "Stretching Scarce Authorizing Legislation as Far as Possible: A Legislative History of the 340B Drug Pricing Program." Sayeh Nikpay @saynikpay and her colleagues went back to the early 1990's to reconstruct the program's origins. Their research draws on interviews with 18 key participants and 175 primary source documents spanning 1990–1992. Their conclusion is difficult to ignore: 340B was originally designed as a narrow policy solution to address an unintended consequence of Medicaid’s best-price provision and to support core safety-net providers. But the paper makes a compelling case that today’s program extends far beyond Congress’s original intent. Whether you support or oppose the current structure of 340B, this paper is essential reading for anyone who wants to understand how we got here. Read it here: drugch.nl/4dVSiTD One especially fascinating detail: The disproportionate share hospital (DSH) eligibility threshold of 11.75% was chosen to qualify two specific hospitals and secure bipartisan support from Senator Hatch and Representative Bliley. In other words, the threshold was not grounded in any broader scientific or policy rationale. Amazing.
8
2
22
4,247
I was joined earlier this year by Franck Le Deu at the PhRMA Forum to discuss China’s accelerating investments in biopharma. China has a plan to lead in medicine development, investing heavily in STEM talent and prioritizing biotech. It’s a reminder that the U.S. cannot take its leadership in innovation for granted.
101
More people are taking a closer look at 340B – and for good reason. A new @FoxBusiness segment highlights concerns about waste, fraud & abuse, rising markups and a lack of accountability in a program that was supposed to help patients.
3
4
23
98,024
The @WSJ Editorial Board highlights a striking line from a recent federal court opinion: North Dakota’s 340B manufacturer mandate law “benefits hospital conglomerates, and Joe Paycheck sees no difference in the price of his meds.” It’s past time we federally reform this broken program. wsj.com/opinion/340b-drug-pr…
2
92
A new PhRMA report finds that while patients in other high-income countries wait nearly 3 years for access to new medicines, U.S. patients wait just 3 months. America’s innovation ecosystem matters for patients in the U.S. and around the world – and we must protect it. phrma.org/blog/new-analysis-…
1
57
Nearly one in four adults experienced a mental health condition in the past year, including more than 30% of young adults. Yet less than half of those living with these conditions receive treatment. Medications, often combined with therapy, help many, but too many people are suffering untreated. During Mental Health Awareness Month, we should be focused on expanding access, reducing stigma and ensuring patients can get the care they need when they need it. ow.ly/iffZ50YYg0W
2
58
GO BIG RED!
Standing at the top. Our highest ranking in school history. 📈
77